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Abstract Heat shock protein 27 (Hsp27) and Hsp70 have been involved in resistance to anticancer drugs in human
breast cancer cells growing in vitro and in vivo. In this study, we examined the expression of Hsp25 (the rodent
homologue to human Hsp27) and Hsp70 in 3 different rodent tumors (a mouse breast carcinoma, a rat sarcoma, and
a rat lymphoma maintained by subcutaneous passages) treated in vivo with doxorubicin (DOX) and lovastatin (LOV).
All tumors showed massive cell death under control untreated conditions, and this massive death increased after
cytotoxic drug administration. In this study, we show that this death was due to classic apoptosis. The tumors also
showed isolated apoptotic cells between viable tumor cells, and this occurred more significantly in the lymphoma. The
tumor type that was more resistant to cell death was the sarcoma, and this was found in sarcomas growing both under
control conditions and after cytotoxic drug administration. Moreover, sarcomas showed the highest expression levels
of Hsp25 in the viable tumor cells growing under untreated conditions, and these levels increased after DOX and LOV
administration. After drug treatment, only sarcoma tumor cells showed a significant increase in Hsp70. In other words,
sarcomas were the tumors with lower cell death, displayed a competent Hsp70 and Hsp25 response with nuclear
translocation, and had the highest levels of Hsp25. In sarcomas, Hsp25 and Hsp70 were found in viable tumor cells
located around the blood vessels, and these areas showed the most resistant tumor cell phenotype after chemotherapy.
In addition, Hsp25 expression was found in endothelial cells as unique feature revealed only in lymphomas. In conclu-
sion, our study shows that each tumor type has unique features regarding the expression of Hsp25 and Hsp70 and
that these proteins seem to be implicated in drug resistance mainly in sarcomas, making these model systems important
to perform more mechanistic studies on the role of Hsps in resistance to certain cytotoxic drugs.
INTRODUCTION
Members of the family of heat shock proteins (Hsps) that
are usually present in tumor cells and tissues have been
implicated in several key processes in tumor biology. For
example, Hsp27 overexpression has been associated with
cell growth arrest and increased differentiation in human
breast cancer biopsy samples (Vargas-Roig et al 1997).
There are 2 responsive elements in the promoter region
of the Hsp27 gene, one responding to estrogens or to es-
trogen receptors and the other to heat shock transcription
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factors. Therefore, the Hsp27 response to estrogens can
explain the association of this protein with higher cell
differentiation not only in breast cancers but also in other
estrogen-responsive tumor tissues (Ciocca et al 1989; Puy
et al 1989). However, Hsp27 expression can also increase
after cell exposure to several stressful conditions (through
the heat shock–responsive elements), and for this reason,
the evaluation of Hsp27 is not a good marker to predict
the responsiveness of human breast cancers to the anti-
estrogen tamoxifen (Ciocca et al 1998). On the other hand,
another member of the Hsp family Hsp70 has been re-
lated with higher cell proliferation and with worse prog-
nosis in breast cancer patients (Ciocca et al 1993; Vargas-
Roig et al 1997). Moreover, both Hsp27 and Hsp70 have
been involved in resistance to the anticancer drug doxo-
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rubicin (DOX) in human breast cancer cells growing in
vitro and in vivo (Ciocca et al 1992; Vargas-Roig et al
1998). At present, this is not surprising because Hsps
have protective roles against thermal stress and other
damaging conditions. There are several proposed mech-
anisms to explain the involvement of Hsp27 and Hsp70
in drug resistance (Ciocca and Vargas-Roig 1997; Ciocca
and Vargas-Roig 2002); however, so far, the most prom-
ising mechanism seems to be the specific requirement of
Hsp70 for the survival of tumor cells (depletion of Hsp70
can activate a tumor-specific death program that is in-
dependent of caspases and bypasses Bcl-2) (Nylandsted
et al 2000). Hsp27 has also been involved in resistance to
apoptosis, blocking mitochondrial cytochrome c release
(Samali et al 2001).
In a previous study in breast cancer patients, DOX in-
duced significant changes in the expression of Hsp27 and
Hsp70, and higher expression levels of these proteins
were associated with drug resistance (Vargas-Roig et al
1998). To gain knowledge on the relationship of these
Hsps with the response of the tumors to chemotherapy
agents, in the present study, we examined the expression
of Hsp25 (the rodent homologue to human Hsp27) and
Hsp70 in 3 different spontaneous rodent tumors (a mouse
breast carcinoma, a rat sarcoma, and a rat lymphoma
maintained by subcutaneous [sc] passages) treated in
vivo with DOX. In addition, it has been previously shown
that lovastatin (LOV) produced a significant inhibition of
metastatic growth and invasiveness on a spontaneous rat
sarcoma and lymphoma, probably through a decrease in
cell adhesion and invasive capacity (Matar et al 1998,
1999). LOV, a drug used in the treatment of patients with
hypercholesterolemia, affects the biosynthetic pathway of
cholesterol. It competitively inhibits 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase, blocking mevalonate syn-
thesis, and the generation of farnesyl groups and of non-
sterol isoprenoids, thus affecting the posttranslational
processing of several proteins (Scharovsky et al 2000). In
the current study, LOV was also administered to the an-
imals with tumors, alone and in combination with DOX.
In this study, immunohistochemistry was used to exam-
ine in detail the expression of Hsp25 and Hsp70 in the
tumor cells that survived the cytotoxic drugs and in the
cells that were suffering death.
MATERIALS AND METHODS
Animals
Inbred adult IIM e/Fm and Fm-m (hereafter referred to
as e and m, respectively) rats (Calderari et al 1991) from
the Facultad de Ciencias Me´dicas, Universidad Nacional
de Rosario breeding facilities, were used. Inbred adult
CBi female mice from the Facultad de Ciencias Me´dicas,
Instituto de Gene´tica Experimental, Universidad Nacional
de Rosario breeding facilities, were used (Di Masso et al
1991). Rats and mice were fed with commercial chow and
water ad libitum and were maintained in a 12-hour light-
dark cycle. All the experiments were developed during
the first half of the light cycle. The animals were treated
in accordance with the guidelines issued by the Canadian
Council on Animal Care.
Drugs
LOV was kindly provided by Laboratorio SIDUS S.A., Ar-
gentina, in the inactive lactone form. It was converted to
the active form by dissolving 480 mg of lactone in 12.5
mL of 968 ethanol, adding 18 mL of 0.1 M NaOH, heating
at 508C for 2 hours, neutralizing the solution with 0.1 M
HCl to pH 7, and adjusting with distilled water to a vol-
ume of 60 mL. Aliquots of this stock solution (20 mM)
were stored frozen at 2208C. DOX was diluted to 1 mg/
mL in saline solution before injection.
Tumors
Lymphoma TACB (L-TACB) is a poorly differentiated B-
cell lymphoma, which arose spontaneously in an inbred
e rat (Celoria et al 1986). It is maintained by serial sc
grafting by trocar of 1 mm3 L-TACB fragments (approx-
imately 106 cells) in syngeneic rats. When L-TACB is in-
jected subcutaneously, lymph nodes are the exclusive
sites of metastatic growth. Sarcoma E-100 (S-E100) is a
fibrosarcoma that appeared spontaneously in an outbred
population of IIM rats in 1955, and it is maintained by sc
passages in rats of the allogeneic inbred line m with 100%
lethality and 0% spontaneous metastasis (Dome´nico et al
1963). Instead, a high incidence of lung metastasis is ob-
served when the same animals are injected intravenously
with S-E100 cells. M-406 is a type B semidifferentiated
mammary adenocarcinoma (Squartini 1979) that shows a
mixed pattern and develops lung and liver metastases. It
arose spontaneously in an inbred CBi female mouse. It is
maintained in vivo by serial intraperitoneal injections of
2.5 3 105 cells in syngeneic mice. In this location, it is
highly invasive to the muscular abdominal wall.
Experimental model
The experimental procedure followed with the 3 tumor
models is as follows. Rats were challenged with L-TACB
or S-E100 and mice with M-406 subcutaneously in the
right flank, by trocar, on day 0, and the animals were
divided into 4 groups and treated as follows—L-TACB:
(1) control animals received no further treatment; (2) in-
jected intraperitoneally with LOV (25 mg/kg of body
weight) daily, from day 0 to 4; (3) injected intraperito-
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neally with DOX (0.25 mg/kg) on day 10; and (4) injected
with LOV 1 DOX as in groups 2 and 3. S-E100: (1) con-
trol; (2) injected intraperitoneally with LOV (25 mg/kg
of body weight) 3 times a week from day 7 to 16; (3)
injected with DOX (2 mg/kg of body weight) twice a
week from day 7 to 16; and (4) LOV 1 DOX as in groups
2 and 3. M-406: (1) control; (2) injected intraperitoneally
with LOV (25 mg/kg of body weight) 3 times a week
from day 5 to 23; (3) injected with DOX (1 mg/kg of body
weight) twice a week from day 5 to 23; (4) LOV 1 DOX
as in groups 2 and 3. The treatment schedules are differ-
ent because we were testing different combinations of
doses and days of administration to achieve, in each tu-
mor model, a maximum antitumor effect with the com-
bination of drugs in nontoxic doses for the animals. The
growth of primary tumors was monitored twice a week.
All the animals were sacrificed on days 21, 18, and 26 for
L-TACB, S-E100, and M-406, respectively, and their tu-
mors resected. The lag time between the end of the drug
treatment and the excision of the tumors was different
(specially for lymphomas); this was due to one of the cri-
teria followed to decide the end of the experiment: the
day on which the control animals reached the maximum
permitted tumor size in an in vivo experiment. However,
because this relatively long lag time may influence the
expression of the Hsps, lymphomas were also taken 3
days after the end of the experiment, which is comparable
with the lag time of sarcomas and mammary carcinomas.
Immunohistochemistry
Tissues were fixed in 10% buffered formalin and embed-
ded in paraffin. For comparative purposes, the tumors
were examined in their largest dimension. Sections of 5–
6 mm thickness were immunostained to reveal Hsp25 and
Hsp70 using an immunoperoxidase method (Dako En-
vision System, Dako Corporation, Carpinteria, CA, USA).
The antibodies used were (1) rabbit polyclonal antibody
against recombinant Hsp25/27, (2) mouse Mab BRM-22
against the constitutive and inducible forms of Hsp70,
and (3) rat Mab 1B5 against the constitutive form of
Hsp70 (Hsc70), kindly provided by Dr A. Laszlo (Mal-
linkrodt Institute of Radiology, Washington University
Medical Center, St Louis, MO, USA). Detailed description
of these antibodies and methods has been published else-
where (Vargas-Roig et al 1998). In addition, in lympho-
mas, blood vessels were examined by immunostaining
with antibodies against FVIII and FXIIIa using commer-
cial antibodies (Dako Corporation). The immunostained
slides were lightly counterstained with hematoxylin and
observed and photographed with an IM35 microscope
(Carl Zeiss, Oberkochen, Germany). The positive reaction
was evaluated considering the location of the specific im-
munostaining on the tumor cells (nuclear, cytoplasmic),
using a semiquantitative grade according to the intensity
of immunostaining and the proportion of stained cells
(Vargas-Roig et al 1998). Briefly, intensity scores are as
follows: no staining, 0; weak staining, 1; moderate stain-
ing, 2; and strong staining, 3. Proportion scores are as
follows: ,1%, 0; 1–10%, 1; 11–30%, 2; 31–66%, 3; and
.66%, 4. Immunostained blood vessels were counted un-
der the 403 objective in the tumor areas showing the
highest positive vessels.
TUNEL technique
Apoptosis was revealed by a modification of the terminal
deoxynucleotidyl transferase-mediated dUTP nick end la-
beling (TUNEL) method, using the ApopTag Plus in situ
detection kit (Oncor, Gaithersburg, MD, USA). These
modifications have been published elsewhere (Cuello-
Carrio´n and Ciocca 1999; Bonfil et al 2001).
Western blot analysis
Western blot was performed on tissue homogenates pre-
pared as reported previously (Vargas-Roig et al 1997).
The protein lysate (20 mg per lane) was subjected to elec-
trophoresis on 12.5% sodium dodecyl sulfate–polyacryl-
amide gels (w/v) and transferred to nitrocellulose mem-
branes. The membranes were incubated with the anti-
bodies against the Hsps (1:2000), and the bands were de-
veloped using chemiluminescence reagents (Dupont
NEN, Boston, MA, USA) and autoradiography film (Sig-
ma, St. Louis, MO, USA).
Statistical analyses
Statistical analyses were performed using the Prism com-
puter program (Graph Pad Software, San Diego, CA,
USA). The tests used were the unpaired t-test and the
Mann-Whitney nonparametric test, with a 2-tailed option
and with 95% confidence interval. A value of P , 0.05
was considered significant.
RESULTS
Tumor sizes and cell death
The tumor sizes of the controls and treated animals, de-
termined on the day of sacrifice, are shown in Table 1.
Although the cytotoxic treatments decreased the tumor
sizes, a statistically significant reduction in tumor size
was observed only in breast carcinomas after the com-
bined treatment with LOV and DOX. However, tumor ar-
eas with massive cell death were observed in the 3 dif-
ferent tumors under study, growing in control conditions
and after cytotoxic drug administration. The detailed
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Table 1 Effect of the different treatments on tumor volume
Tumors
Days after last
drug injection
Tumor volume (cm3)a mean 6 SE
Control DOX LOV LOV 1 DOX
Breast carcinoma
Sarcoma
Lymphomac
Lymphomad
3
2
18
3
3.08 6 0.62
25.38 6 4.21
34.47 6 8.28
19.03 6 3.33
2.72 6 0.35
18.85 6 1.05
30.00 6 6.76
22.15 6 2.10
2.15 6 0.39
22.15 6 4.95
49.81 6 6.86
27.74 6 13.87
1.80 6 0.24b
18.09 6 1.13
25.30 6 7.86
14.34 6 9.34
DOX, doxorubicin; LOV, lovastatin.
a Tumor volume measured at the end of the experiment on the day indicated in the second column.
b Student’s t-test: control vs LOV 1 DOX; P , 0.05.
c d Identical experiments but ending 18 and 3 d after the last injection, respectively.
Fig 1. Apoptosis in the 3 tumor types under study. (A) Breast carcinoma growing under control untreated conditions. A large area with
massive cell death (a) is seen. Note that the cells display the morphological characteristics of classic apoptosis. t, viable tumor cells.
Hematoxylin staining. (B) Breast carcinoma treated with doxorubicin (DOX) and lovastatin. The TUNEL technique stained in dark, both a
large area of massive apoptosis (a) and an isolated apoptotic cell (arrowhead in the area of viable tumor cells, t). TUNEL technique with
hematoxylin counterstaining. (C) Sarcoma treated with DOX. There are 2 foci of dead cells (a) displaying the morphological characteristics
of classic apoptosis. This tissue section was immunostained to reveal Hsp70 that was absent in apoptotic cells and present in some tumor
cells (seen as dark cells in the upper right corner, t). Hematoxylin counterstaining. (D) Lymphoma treated with DOX. The TUNEL technique
stained in dark numerous apoptotic cell (arrowheads). TUNEL technique with hematoxylin counterstaining. For comparative purposes, all
micrographs are at 1203 magnification.
morphological analysis of these areas revealed that most
of the tumor cells were dying by classic apoptosis (Fig 1
A,C), and very few cells displayed morphological char-
acteristics of apoptosis-like programmed cell death and
of necrosis (death types reviewed by Leist and Ja¨a¨ttela¨
2001). This finding was confirmed by the in situ TUNEL
technique (Fig 1 B,D). The evaluation of the massive ap-
optotic areas revealed that control untreated tumors
showed different degrees of massive apoptosis. Breast
carcinomas showed almost a 2-fold increase in massive
apoptosis compared with sarcomas, whereas lymphomas
showed 1.5-fold increase compared with sarcomas (Fig
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Fig 2. Massive apoptosis in untreated tumors and in tumor treated with doxorubicin and lovastatin. The scores used were: (1) ,10%, (2)
11–33%, (3) 34–66%, and (4) .66%. These scores represent the area (in percentage) showing massive apoptosis, evaluating the entire
tumor (examining the tumors in their largest dimension). For instance, there were tumors where 50% of the tissue section was occupied by
massive apoptosis (in this case the score was 3).
Fig 3. Isolated apoptosis in untreated tumors and in tumors treated with doxorubicin and lovastatin. The scores reflect the number of
apoptotic cells per 1000 tumor cells (evaluated in the areas of viable tumor cells).
2). In breast carcinomas, massive apoptotic areas were
clearly seen in the center of tumor cell clusters, whereas
in sarcomas and lymphomas, areas of massive apoptosis
occurred at random without a special arrangement of the
viable tumor cells. It was of interest to evaluate the level
of massive apoptosis after the different drug treatments.
In breast carcinomas, massive apoptosis increased signif-
icantly (P , 0.05) after DOX treatment and even more in
the tumors treated with the combination of LOV and
DOX (P , 0.01) (Fig 2). LOV alone was also effective in
increasing massive apoptosis but at lower level than was
DOX alone (P , 0.05). In sarcomas and lymphomas, DOX
significantly increased massive apoptosis (P , 0.05) but
at lower levels than in breast carcinomas. In these tumors,
LOV increased massive apoptosis but without reaching
statistical significance and slightly increased apoptosis
when administered in combination with DOX (Fig 2).
Isolated apoptotic cells were also observed intermin-
gled in the viable tumor areas, appearing as single dead
cells (Fig 1B) or as small apoptotic cell clusters (Fig 1C).
The difference in magnitude of dead cells found as iso-
lated (or small clusters) apoptosis vs massive apoptosis
ranged in the order of 1:100 to 1:1000. Although massive
apoptosis was significantly higher than isolated apopto-
sis, the latter might be significant in tumor biology, and
for this reason it was also evaluated. Different levels of
isolated apoptosis were found in the 3 tumor types stud-
ied (Fig 3). Under control conditions, sarcomas showed
the lowest level of isolated apoptosis, whereas lympho-
mas showed the highest levels. In animals treated with
DOX alone or in combination with LOV, breast carcino-
mas showed more isolated apoptosis than did control tu-
mors (P , 0.05) (Fig 3). In sarcomas, the drug treatments
did not induce significant changes, and isolated apoptosis
remained at very low levels. In contrast, in lymphomas,
DOX increased isolated apoptosis and even more when
administered in combination with LOV (P , 0.001) (Fig
3).
Heat shock protein 25
In untreated breast carcinomas, viable tumor cells lacked
Hsp25 (Fig 4A). In areas of massive apoptosis, the protein
was strongly positive, appearing in apoptotic cells (Fig
4A) and only occasionally in ‘‘viable’’ tumor cells located
in the immediate vicinity of apoptotic cells. Most of the
isolated apoptotic cells located between the viable tumor
cells lacked Hsp25. Western blotting could not discrimi-
nate the detailed occurrence of Hsp25 (or Hsp70) in the
tumors. We have used the antibodies in Western blot be-
fore (Ciocca et al 1989, 1993), but in the present study, for
the detailed analysis of the Hsps in the viable tumor cells
and in the apoptotic cells, Western blot was not useful,
and for this reason we continued this study by immu-
nohistochemistry. In contrast to breast carcinomas, in un-
treated sarcomas, viable tumor cells expressed Hsp25
(Fig 4B). Table 2 shows the average expression of Hsp25
in the cytoplasm and nucleus of viable tumor cells. Hsp25
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Fig 4. Hsp25 expression in spontaneous rodent tumors (immunostaining for Hsp25 with hematoxylin counterstaining). (A) Breast carcinoma
growing under control untreated conditions. The viable tumor cells (t) lacked Hsp25 expression, whereas apoptotic cells (a) showed immu-
nostaining. (B) Tissue section from an untreated sarcoma. Note Hsp25 expression in numerous tumor cells (dark cells) and the presence of
some apoptotic cells lacking the protein (right side). (C) Untreated control lymphoma showing numerous small vessels with Hsp25 in endo-
thelial cells. These vessels lacked FVIII immunostaining. (D) In this breast carcinoma treated with doxorubicin (DOX) the viable tumor cells
(t) and the apoptotic cells (a) lack Hsp25 expression. (E) Tissue section from a sarcoma treated with DOX. Note that most of the tumor cells
express Hsp25. (F) Lymphoma treated with DOX. Hsp25 can be observed in the endothelium of small vessels, but the number of positive
vessels decreased when compared with untreated tumors (shown in C). (G) Sarcoma treated with DOX showing cells with strong Hsp25
expression (arrowheads). (H) Sarcoma treated with lovastatin and DOX. The tumor cells located around the blood vessel (V) are the cells
that express more Hsp25. For comparative purposes, all micrographs are at 1203 magnification except C and F that were taken at lower
magnification (603).
was absent in areas of massive apoptosis and in isolated
apoptotic cells between the viable tumor cells (Fig 4B).
Finally, in untreated lymphomas, Hsp25 was absent in
viable tumor cells and in tumor cells dying in massive
and in isolated apoptoses. It is of interest to mention that
the endothelium of the blood vessels located between the
tumor cells showed Hsp25 immunostaining (Fig 4C).
Western blotting was not sensitive enough to reveal the
Hsp25 found in the blood vessels by immunohistochem-
istry.
In DOX-treated breast carcinomas, Hsp25 could be de-
tected in the cytoplasm of viable tumor cells but with
weak staining and in few cells (Table 2). In the areas of
massive apoptosis, in contrast to control tumors, Hsp25
was absent in apoptotic cells (Fig 4D). We already men-
tioned that these massive apoptotic areas were larger
than those observed in the control tumors. Moreover,
DOX-induced apoptosis appeared as an accelerated phe-
nomenon with lakes and masses of confluent chromatin
compaction. Hsp25 expression was weak and remained
in very few tumor cells, limiting the massive apoptotic
areas. Individual apoptosis between viable tumor cells
was Hsp25 negative. In DOX-treated sarcomas, viable tu-
mor cells had expression levels of Hsp25 similar to those
observed in the controls (Fig 4E); however, there were
areas of viable tumor cells with Hsp25 expression in the
nuclei (Table 2). Tumor cells at the borders of massive
apoptotic areas adopted elongated appearance, and some
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Table 2 Viable tumor cells, Hsp25 expression in untreated tumors and in tumors treated with doxorubicin (DOX) and lovastatin (LOV)
Tumor
Untreated
Ca N
DOX
C N
LOV
C N
LOV 1 DOX
C N
Breast carcinoma
Sarcoma
Lymphoma
0b
1 1 3
0
0
0
0
1 1 1
1 1 2
0
0
1 1 1
0
1 1 1
1 1 2
0
0
1 1 1
0
1 1 1
2 1 2
0
0
1 1 2
0
a C, cytoplasmic; N, nuclear.
b The score used is explained in Materials and Methods. Numbers on the left and right correspond to Intensity and Proportion scores,
respectively. The scores represent the average of 6 animals in each group.
Table 3 Hsp25-positive vessels in lymphomas
Untreated Doxorubicin Lovastatin
Lovastatin 1
doxorubicin
18.8 6 1.1 14.9 6 2.2 16.24 6 1.7 13.3 6 1.17
The score used is explained in Materials and Methods. Numbers
are mean 6 SE. Doxorubicin treatment significantly decreased (P ,
0.05), the number of Hsp25 vessels and more significantly when
associated with lovastatin (P , 0.01), in both cases when compared
with the control group. The scores represent the average of 6 ani-
mals in each group. In lymphomas, factors VIII and FXIIIa did not
reveal the endothelium of the blood vessels as did Hsp25.
Fig 5. Hsp25 expression levels in viable tumor cells in untreated tumors and in tumors treated with doxorubicin (DOX) and lovastatin (LOV).
The values represent the sum of the Hsp25 content in the cytoplasmic and nuclear cell compartments (using the evaluation scores explained
in Materials and Methods). Note that sarcomas had the higher Hsp25 expression levels and that the levels changed after drug administration
(Hsp25 was significantly higher [P , 0.001] in the group treated with LOV and DOX than in the control group).
of them had strong Hsp25 expression (Fig 4G). Isolated
apoptotic cells between the viable tumor cells were Hsp25
negative. In DOX-treated lymphomas (obtained 3 or 11
days after treatment), only blood vessels showed Hsp25
expression (Fig 4F), and the number of Hsp25-positive
vessels changed with the different treatments (Table 3).
LOV-treated breast carcinomas showed characteristics
similar to those observed in DOX-treated group. In LOV-
treated sarcomas, viable tumor cells showed higher
Hsp25 expression than did controls because of the pres-
ence of weak but noticeable Hsp25 expression in the nu-
clear compartment. Massive apoptosis was Hsp25 nega-
tive or very weakly positive. The tumor cells surrounding
the areas of massive apoptosis were Hsp25 positive in
areas of cells changing their appearance to more elon-
gated form. In these areas, Hsp25 appeared in the cyto-
plasm and, sometimes, in the nuclei of tumor cells. In-
dividual apoptosis lacked Hsp25. LOV-treated lympho-
mas (obtained 3 or 11 days after treatment) lacked Hsp25
in viable tumor cells as well as in massive and individual
apoptoses, but the protein remained in endothelial cells
of blood vessels (Table 3).
In LOV- and DOX-treated breast carcinomas, viable tu-
mor cells showed very low levels of Hsp25 expression
(Table 2). Massive apoptosis displayed weak immuno-
staining for Hsp25, and periapoptotic cells were occa-
sionally positive in the cytoplasm and the nucleus. Most
of the individual apoptosis was Hsp25 negative. In LOV-
and DOX-treated sarcomas, viable tumor cells had more
Hsp25 than did controls (Table 2). Figure 5 shows the
total Hsp25 content in the tumors. Massive apoptosis ar-
eas were Hsp25 negative, but the tumor cells surrounding
the areas of massive apoptosis had Hsp25 expression in
certain areas, mainly those around the vascular tracts (Fig
4H) and in cells changing their appearance to more elon-
gated form. Individual apoptosis was Hsp25 negative.
LOV- and DOX-treated lymphomas (obtained 3 or 11 days
after treatment) lacked Hsp25 in viable tumor cells and
in massive and individual apoptoses, and the protein re-
mained in endothelial cells of blood vessels but at lower
levels than in the controls (Table 3).
Heat shock protein 70
In untreated breast carcinomas, viable tumor cells ex-
pressed Hsp70 in the cytoplasm and nucleus (Table 4). In
areas of massive apoptosis, the protein was positive in
apoptotic cells, displaying a lesser degree of damage, and
it was absent in areas with more advanced deterioration
(cells displaying the corpses without the compact nuclear
fragments). Sometimes, groups of tumor cells located in
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Table 4 Viable tumor cells, Hsp70 expression in untreated tumors and in tumors treated with doxorubicin (DOX) and lovastatin (LOV)
Tumor
Untreated
Ca N
DOX
C N
LOV
C N
LOV 1 DOX
C N
Breast carcinoma
Sarcoma
Lymphoma
2 1 1b
1 1 2
1 1 2
2 1 2
1 1 2
1 1 2
2 1 1
2 1 2
2 1 2
1 1 2
1 1 2
1 1 2
1 1 2
1 1 1
1 1 2
1 1 2
2 1 3
1 1 2
2 1 2
2 1 4
2 1 2
1 1 2
2 1 4
1 1 2
a C, cytoplasmic; N, nuclear.
b The score used is explained in Materials and Methods. Numbers on the left and right correspond to Intensity and Proportion scores,
respectively. The scores represent the average of 6 animals in each group.
Fig 6. Hsp70 expression in spontaneous rodent tumors (immunostaining for Hsp70 with hematoxylin counterstaining). (A) Untreated sar-
coma. Hsp70 can be seen in the nuclei of many viable tumor cells, whereas massive apoptotic cells (right side) lacked the protein. (B)
Untreated sarcoma. Several macrophages showed Hsp70 in the cytoplasm; they were intermingled with small, round, viable sarcoma tumor
cells and apoptotic cells. (C) Breast cancer treated with lovastatin (LOV) and doxorubicin (DOX). Hsp70 can be observed in the nuclei and
cytoplasm of breast cancer cells that escaped apoptosis after chemotherapy. (D) Sarcoma treated with LOV and DOX. Viable tumor cells
located around blood vessels (*) showed strong nuclear and cytoplasmic expressions of Hsp70.
the immediate vicinity of massive apoptosis showed
Hsp70 in the nuclei and cytoplasm; however, most of the
viable tumor cells close to massive apoptosis lacked
Hsp70. Moreover, most of the isolated apoptotic cells
lacked Hsp70. In untreated sarcomas, Hsp70 was ob-
served in the cytoplasm and nucleus of viable tumor cells
at similar levels than that observed in breast carcinomas
(Table 4). In areas of massive apoptosis, the most impor-
tant observation was the increase in Hsp70 content in the
nuclei of cells in the vicinity of apoptosis (Fig 6A). Apo-
ptotic cells, both isolated and in areas of massive apopto-
sis, were inconstant regarding Hsp70 expression. Most of
them lacked the protein; however, apoptotic corpses had
Hsp70 expression. Sometimes, large cells with features of
phagocytosis showed Hsp70 expression (Fig 6B). In un-
treated lymphomas, viable tumor cells expressed Hsp70
(Table 4). In contrast, apoptotic cells lacked the protein.
In DOX-treated breast carcinomas, Hsp70 could be de-
tected in the nucleus and cytoplasm of viable tumor cells
(Table 4). Figure 7 shows the total Hsp70 content in the
viable tumor cells. Hsp70 was inconstantly observed in
cells in the areas of massive apoptosis and in individual
apoptotic cells. In DOX-treated sarcomas, Hsp70-positive
cells tended to be arranged surrounding blood vessels,
and the total Hsp70 content increased with respect to
control tumors (Fig 7). Massive apoptosis and individual
apoptosis were in general Hsp70 negative. DOX-treated
lymphomas (obtained 3 or 11 days after treatment)
showed Hsp70 expression in viable tumor cells (Table 4).
Massive and individual apoptoses did not show Hsp70
expression.
In LOV-treated breast carcinomas, Hsp70 expression
was detected in viable tumor cells, mainly in the nuclei
(Table 4). Hsp70 was inconstantly observed in cells in ar-
Cell Stress & Chaperones (2003) 8 (1), 26–36
34 Ciocca et al
Fig 7. Hsp70 expression levels in viable tumor cells in untreated tumors and in tumors treated with doxorubicin (DOX) and lovastatin (LOV).
The values represent the sum of the Hsp70 content in the cytoplasmic and nuclear cell compartments (using the evaluation scores explained
in Materials and Methods). In sarcomas, note the increase in Hsp70 expression in doxorubicin-treated tumors and mainly in LOV- and DOX-
treated tumors with respect to control tumors (P , 0.05 and P , 0.001, respectively).
eas of massive apoptosis and in individual apoptotic
cells. In LOV-treated sarcomas, Hsp70-positive cells tend-
ed to be arranged surrounding blood vessels. Massive
apoptosis and individual apoptosis were in general
Hsp70 negative or weakly positive. LOV-treated lympho-
mas (obtained 3 or 11 days after treatment) showed
Hsp70 expression in viable tumor cells (Table 4). Massive
and individual apoptoses did not show significant Hsp70
expression.
In LOV- and DOX-treated breast carcinomas, Hsp70 ex-
pression in viable tumor cells was seen in cell clusters
(Fig 6C). The total content of this protein showed a ten-
dency to increase with respect to the other groups but
without reaching statistical significance (Fig 7). Hsp70
was inconstantly observed in cells in the areas of massive
apoptosis and in individual apoptotic cells. In LOV- and
DOX-treated sarcomas, Hsp70-positive cells showed a
predominance to be located surrounding blood vessels
(Fig 6D). Total Hsp70 content increased with respect to
the other groups (Fig 7). Massive apoptosis and individ-
ual apoptosis were in general Hsp70 negative. LOV- and
DOX-treated lymphomas (obtained 3 or 11 days after
treatment) showed Hsp70 expression in viable tumor cells
(Table 4). Massive and individual apoptoses did not show
significant Hsp70 expression.
Because the antibody against Hsp70 BRM22 used in
the present study recognizes both Hsc70 and Hsp70, a
specific antibody against Hsc70 was also tested in the
tumor samples. The immunostaining of serial tumor sec-
tions with both antibodies showed that Hsc70 represent-
ed about 35–55% of the total Hsp70 content revealed by
the BRM22 antibody.
DISCUSSION
Resistance to cytotoxic chemotherapeutic drugs is a major
problem in the treatment of several types of cancers, and
Hsps have been implicated among the molecular mech-
anisms of drug resistance. In this study, we found that
the sarcoma was the tumor type that was more resistant
to cell death, and this was noted in sarcomas growing
both under control conditions and after cytotoxic drug
administration. Sarcomas showed the highest expression
levels of Hsp25 in the viable tumor cells growing under
untreated conditions, and these levels increased after
drug administration. This result is consistent with the
concept that Hsp25 is implicated in survival of tumor
cells (Ciocca et al 1992; Vargas-Roig et al 1997; Hansen
et al 1999). Hsp25 has been found associated with en-
zymes of the base excision repair mechanism in HeLa
cells (Mendez et al 2000) and involved in resistance to
apoptosis (Samali et al 2001; Arrigo et al 2002). We also
found that the expression levels of Hsp70 were similar in
the 3 tumor types under control conditions but, after che-
motherapy administration, only sarcoma tumor cells
showed a significant increase in Hsp70 (of which a con-
siderable amount, about 35–55%, was Hsc70). In other
words, sarcomas were the tumors with lower cell death,
which displayed a competent Hsp70-Hsc70 and Hsp25
response, and had the highest levels of Hsp25 expression.
The resistance of sarcomas to cell death after chemother-
apy is in agreement with clinical situations; these tumors
are usually more resistant to chemotherapy than are lym-
phomas and breast carcinomas.
In the present study, we found, in the 3 different tumor
types, that cancer cells were dying by classic apoptosis.
Massive apoptosis was the main phenomenon observed.
However, apoptosis in isolated tumor cells (more signif-
icantly in lymphomas) was also observed The spontane-
ous apoptosis observed in untreated tumors, which could
be triggered by many factors (eg, mild ischemia), was
notably increased by the cytotoxic drugs. In previous
studies, it has been pointed out that all the anticancer
drugs can induce apoptosis (Hickman 1996). LOV affects
the formation of farnesyl residues, decreasing the post-
translational processing (prenylation) of several proteins
(including the p21ras oncoprotein) (Rozados et al 2000),
and this may decrease the survival signaling in favor of
apoptosis (Hickman 1996; Du et al 1999). Then, LOV
through this effect may synergistically act with DOX to
increase cell killing as noted in our study. It is of interest
that in breast carcinomas, Hsp25 was clearly observed in
Cell Stress & Chaperones (2003) 8 (1), 26–36
Hsp25 and Hsp70 in tumors treated with chemotherapy 35
the tumor cells with spontaneous massive apoptosis. The
content of this Hsp decreased in treated tumors, perhaps
because of the accelerated cell death induced by the cy-
totoxic drugs (apoptotic cells showed more advanced
damage). In the future, it will be of interest to explore in
detail the kinetic of Hsp25 expression during apoptosis.
Therefore, our study presents evidence that in certain tu-
mor types, Hsp25, rather than protecting the cells, par-
ticipates in apoptosis as a late molecular event, perhaps
tagging or routing the damaged proteins (or both) (or
degrading enzymes) to the proteosomes or lysosomes cel-
lular degrading systems.
Our detailed microscopic analysis revealed that many
viable tumor cells close to apoptosis presented a trans-
location of Hsp25 and Hsp70 proteins to the nuclei. In
this cellular location, there are important proteins that are
in need of chaperones for maintaining their proper fold-
ing and for guiding their movements and interactions
with deoxyribonucleic acid. This translocation was main-
ly observed in sarcomas.
This study revealed that not all viable tumor cells close
to apoptosis expressed the Hsps, indicating that massive
apoptosis is not affecting Hsp25 or Hsp70 expression in
neighboring cells. This observation was more obvious in
lymphomas and breast carcinomas. We also found that in
breast carcinomas and lymphomas, there were tumor
cells that escaped the action of the cytotoxic drugs and
that did not express Hsp25 while Hsp70 levels remained
stable. This finding suggests that other molecular mech-
anisms are protecting these cells from death. There are
many molecular mechanisms that protect the tumor cells
from chemotherapy (Bernal 1997). However, it is clear
that in sarcomas, Hsp25 and Hsp70 are found in viable
tumor cells located around the blood vessels. Interesting-
ly, these are the areas that showed the most resistant tu-
mor cell phenotype after chemotherapy. Finally, we found
in lymphomas a unique feature: the expression of Hsp25
in endothelial cells, which was affected by the treatment
with LOV and DOX. At present, we do not know the
biologic significance of Hsp25 in endothelial cells of lym-
phomas. In conclusion, our study shows that each tumor
type has unique features regarding the expression of
Hsp25 and Hsp70 and that these proteins seem to be im-
plicated in drug resistance mainly in sarcomas, whereas
in breast carcinomas, Hsp25, rather than protecting the
cells, could have a role in apoptosis as a late molecular
event.
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